0


绕过现有凝血分析限制的新型试剂

Novel reagents to bypass limitations of existing clotting assays
课程网址: http://videolectures.net/kolokviji_majumder_nrbl/  
主讲教师: Rinku Majumder
开课单位: 北卡罗来纳大学
开课时间: 2010-10-10
课程语种: 英语
中文简介:
血液凝固是身体保护血管完整性的手段。定期进行临床试验或凝血试验以表征出血性疾病如血友病A和Bbut,但目前由于某些患者的血液中存在干扰而受限。迫切需要开发一种可重复,可靠并且可用于患有狼疮剂的患者的凝血测定法。基于几十年的基础研究在矿井的凝血酶原复合物,由丝氨酸蛋白酶,Xa因子(FXa的)的监管和蛋白质辅助因子,因子Va(的FVa)比沃特可溶性磷脂酰丝氨酸(PS),我们已经制定并开始所以研究一种令人兴奋的新型PS化合物,含有仅六个碳的饱和二酰基链(C6PS)。使用这种可溶性PS分子,我们可以在ceratin环境下使用以避免由卵抗凝剂引起的限制,并且我们已经获得了该新试剂的美国专利。该试验的成功开发将减少出血性疾病的误诊率,并且将不再需要昂贵的后续检测。
课程简介: Blood clotting is the mean by which the body protects the integrity of blood vessels. Clinical tests, or clotting assays, are regularly performed to characterize bleeding disorders such as hemophilia A and B but are currently limited due to interferences present in the blood of some patients. There is a pressing need to develop a coagulation assay that is reproducible, reliable and that can be used for patients containing Lupus agents. Based on several decades of basic research in the regulation of the prothrombinase complex, which consists of a serine protease, factor Xa (FXa), and a protein cofactor, factor Va (FVa) by water soluble Phosphatidyl Serine (PS), we have developed and started to study an exciting novel PS compound containing saturated diacyl chains of only six carbons (C6PS). Using this soluble PS molecule, we have been able under ceratin circumstances to bypass the limitations caused by lupus anticoagulants and we have already obtained an US Patent for this novel reagent. Successful development of this assay will decrease misdiagnoses of bleeding disorders and will remove the need for expensive subsequent testing.
关 键 词: 临床试验; 凝血试验; 出血性疾病
课程来源: 视频讲座网
最后编审: 2020-07-16:yumf
阅读次数: 78